TrialNature medicine2021

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

Michael E Nassif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.